2018 Pulmonary Embolism Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Pulmonary Embolism Market
Pulmonary Embolism refers to a heart condition in the arteries transporting blood to the lungs are blocked, causing sudden shortness of breath and chest pain. The prevalence rates in the US are around 0.08%. Clinical symptoms of the disease include pulse less electrical activity to mild dyspnea. On the basis of severity, Pulmonary Embolism is classified as massive, sub-massive and low types. Anticoagulants are primarily administered to the patients.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Pulmonary Embolism pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Pulmonary Embolism pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Pulmonary Embolism pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Pulmonary Embolism pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Pulmonary Embolism pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Pulmonary Embolism pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 PULMONARY EMBOLISM PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Pulmonary Embolism Pipeline Snapshot
2.3 Pulmonary Embolism Pipeline by Phase
2.4 Pulmonary Embolism Pipeline by Company
2.5 Pulmonary Embolism Pipeline by Mechanism of Action
3 PULMONARY EMBOLISM- COMPANY WISE PIPELINE ANALYSIS
Daiichi Sankyo Co Ltd
Dong-A Socio Holdings
ST Pharm Co.,Ltd.
Tasly Phar. International Co., Ltd
TeaRx Ltd.
Verseon Corp
4 PULMONARY EMBOLISM R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PULMONARY EMBOLISM PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 PULMONARY EMBOLISM PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Pulmonary Embolism Pipeline Snapshot
2.3 Pulmonary Embolism Pipeline by Phase
2.4 Pulmonary Embolism Pipeline by Company
2.5 Pulmonary Embolism Pipeline by Mechanism of Action
3 PULMONARY EMBOLISM- COMPANY WISE PIPELINE ANALYSIS
Daiichi Sankyo Co Ltd
Dong-A Socio Holdings
ST Pharm Co.,Ltd.
Tasly Phar. International Co., Ltd
TeaRx Ltd.
Verseon Corp
4 PULMONARY EMBOLISM R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PULMONARY EMBOLISM PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Pulmonary Embolism Pipeline by Phase, H2- 2018
Figure 2: Pulmonary Embolism Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Pulmonary Embolism Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Pulmonary Embolism Pipeline by Phase, H2- 2018
Figure 2: Pulmonary Embolism Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Pulmonary Embolism Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Pulmonary Embolism Pipeline by Phase, H2- 2018
Pulmonary Embolism Pipeline by Companies, H2- 2018
Pulmonary Embolism Pipeline by Mechanism of Action, H2- 2018
Table 1: Daiichi Sankyo Co Ltd Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 2: Dong-A Socio Holdings Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 3: ST Pharm Co.,Ltd. Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 4: Tasly Phar. International Co., Ltd Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 5: TeaRx Ltd. Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 6: Verseon Corp Pulmonary Embolism Pipeline Drugs, H2- 2018
Pulmonary Embolism Pipeline by Phase, H2- 2018
Pulmonary Embolism Pipeline by Companies, H2- 2018
Pulmonary Embolism Pipeline by Mechanism of Action, H2- 2018
Table 1: Daiichi Sankyo Co Ltd Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 2: Dong-A Socio Holdings Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 3: ST Pharm Co.,Ltd. Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 4: Tasly Phar. International Co., Ltd Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 5: TeaRx Ltd. Pulmonary Embolism Pipeline Drugs, H2- 2018
Table 6: Verseon Corp Pulmonary Embolism Pipeline Drugs, H2- 2018
